ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Lancet Infect Dis · 2026-05-06

Phase 4 trial in 221 UK infants: 4CMenB at 8 and 12 weeks v 8 and 16 weeks gave similar protective hSBA titre rates 4 weeks post-primary for all strains (eg PorA 64% v 75%, NS), but lower titres; the reduced-interval schedule caused less irritability and crying.

RCTn = 221 infants
Thorn et al. Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial
Infectious diseases · Lancet Microbe · 2026-02-13

Phase 4 challenge trial in healthy adults: 1 month after vaccination, PCV13 gave a non-significant reduction in serotype 3 colonisation vs placebo (56% vs 65%; RR 0.84, 0.70-1.01). PPV23 showed no protection; PCV13 cut serotype 6B colonisation at 6 months (RR 0.40).

RCTn = 407
Liatsikos et al. The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.